Patients Sue GLP-1 Drugmakers Over Risk of Sudden Vision Loss
Some countries have compelled Novo Nordisk and Eli Lilly to include warnings or information about NAION, a rare vision-loss condition, on their GLP-1 drug labels. There is no NAION warning on the drugs’ labels in the U.S., though the Food and Drug Administration is investigating a potential link. Novo Nordisk and Eli Lilly face lawsuits from patients claiming the medications caused the condition, but both companies are fighting the litigation.


Bengali (Bangladesh) ·
English (United States) ·